From the Department of Orthopaedic Surgery (Dr. Chapman and Dr. Zuckerman), Loma Linda University Health, and the Department of Medicine & Basic Science (Dr. Mirshahidi), Loma Linda University Cancer Center, Biospecimen Laboratory, Loma Linda, CA.
J Am Acad Orthop Surg. 2019 Apr 1;27(7):e337-e345. doi: 10.5435/JAAOS-D-17-00407.
Bupivacaine is a commonly used local anesthetic that has been shown to be cytotoxic to articular chondrocytes and various tumor cells. This study evaluates the in vitro effects of bupivacaine on cartilaginous tumor cells.
Multiple different cartilaginous tumors were evaluated, including enchondromas, chondroblastomas, a low-grade chondrosarcoma, which were harvested from patients during tumor resection, and a grade-II chondrosarcoma SW1535 (ATCC HTB-94). The tumor cells were treated with 0.25% and 0.5% bupivacaine at various times points, and the result was compared with that of untreated tumor cells. Tumor cell viability and apoptosis were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and flow cytometry.
The tumors were analyzed in groups according to their pathologic diagnosis. Increasing periods of exposure to bupivacaine decreased the cell viability in all tumor samples. The cytotoxicity of 0.5% bupivacaine was significantly greater than that of 0.25% bupivacaine in all tumor cells tested.
At clinically relevant concentrations, in vitro exposure to bupivacaine caused a decrease in cellular viability and an increase in the induction of apoptosis in a dose- and time-dependent manner in each of the tumor cells evaluated in this study.
布比卡因是一种常用的局部麻醉剂，已被证明对关节软骨细胞和各种肿瘤细胞具有细胞毒性。本研究评估了布比卡因对软骨肿瘤细胞的体外影响。
评估了多种不同的软骨肿瘤，包括内生软骨瘤、软骨母细胞瘤、低度软骨肉瘤，这些肿瘤均在肿瘤切除过程中从患者身上采集，并使用了二级软骨肉瘤 SW1535（ATCC HTB-94）。将肿瘤细胞用 0.25%和 0.5%布比卡因处理不同时间点，并将结果与未经处理的肿瘤细胞进行比较。通过 MTT（3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴盐）检测和流式细胞术评估肿瘤细胞活力和凋亡。
根据病理诊断对肿瘤进行分组。暴露于布比卡因的时间延长会降低所有肿瘤样本中的细胞活力。在所有测试的肿瘤细胞中，0.5%布比卡因的细胞毒性明显大于 0.25%布比卡因。
在临床相关浓度下，体外暴露于布比卡因以剂量和时间依赖的方式导致本研究中评估的每种肿瘤细胞的细胞活力降低和细胞凋亡增加。
